Annovis Bio News

Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results

TipRanksMay 15 06:46 ET

Annovis Bio Analyst Ratings

BenzingaMay 13 07:48 ET

Buy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson's Treatment

TipRanksMay 13 06:18 ET

Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)

TipRanksApr 30 06:33 ET

Annovis Bio Analyst Ratings

BenzingaApr 30 06:23 ET

Annovis Bio Analyst Ratings

BenzingaApr 2 08:56 ET

Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer's and Parkinson's Treatments

TipRanksApr 2 06:25 ET

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)

TipRanksMar 21 15:10 ET

Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)

TipRanksMar 21 07:40 ET

Annovis Bio Analyst Ratings

BenzingaMar 21 06:20 ET

Annovis Bio Stock Downgraded to Hold With $9 Price Target

InvestingFeb 28 13:38 ET

Annovis Bio Analyst Ratings

BenzingaFeb 28 06:49 ET

Maintaining Hold on Annovis Bio Amid Phase 3 Parkinson's Trial Concerns and Financial Uncertainties

TipRanksFeb 28 04:55 ET

Buy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial Prospects

TipRanksFeb 15 13:35 ET

Analysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY)

TipRanksFeb 15 13:30 ET

Buy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD Trials

TipRanksFeb 15 06:25 ET

Optimistic Outlook for Annovis Bio With Buy Rating Amid Promising Clinical Trials

TipRanksJan 29 06:25 ET

Canaccord Genuity Initiates Coverage On Annovis Bio With Buy Rating, Announces Price Target of $36

BenzingaDec 29, 2023 05:43 ET

Annovis Bio Analyst Ratings

BenzingaDec 29, 2023 05:39 ET

Buy Rating Affirmed for Annovis Bio Amidst Strong Clinical Trial Progress and Robust Financial Position

TipRanksNov 29, 2023 11:15 ET